Ligand Pharmaceuticals Inc. (LGND) Dividend History

Ligand Pharmaceuticals Inc. (LGND) is a biopharmaceutical company that focuses on the development and acquisition of technology platforms and proprietary products for the advancement of innovative medicines. The company partners with other pharmaceutical firms to develop and commercialize drug candidates, leveraging its expertise in biology, chemistry, and process development to streamline drug discovery and development.

3911 Sorrento Valley Blvd, San Diego, CA, 92121
Phone: 858-550-7500

Dividend History

Pay Date Amount Ex Dividend Date Record Date
July 01, 2010 $0.08 07/02/2010 06/28/2010
April 19, 2007 $2.50 04/03/2007 04/05/2007

Dividends Summary

  • Ligand Pharmaceuticals Inc. has issued 2 dividend payments over the past 3 years
  • The most recent dividend was paid 5546 days ago, on July 1, 2010
  • The first recorded dividend was paid on April 19, 2007
  • The highest dividend payout was $2.50 per share
  • The average dividend over this 3 year span is $1.29 per share
  • Ligand Pharmaceuticals Inc. has decreased its dividend payments by 96.95% since 2007

Company News

  • Ligand to Participate in September Investor Conferences

    Ligand Pharmaceuticals executives will participate in two upcoming investor conferences: Citi 20th Annual BioPharma Conference in Boston and H.C. Wainwright 27th Annual Global Investment Conference in New York, presenting and hosting investor meetings.

    GlobeNewswire Inc.
    Featured Companies: AMGN BAX GILD JAZZ MRK PFE
  • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

    Palvella Therapeutics, a clinical-stage biopharmaceutical company, has appointed Matthew E. Korenberg as its new Chief Financial Officer. Korenberg brings over 27 years of senior executive experience in the biotech and healthcare investment banking industries.

    Benzinga
    Featured Companies: LFCR
  • LGND reaches 52-week high, hitting $103.295 - Investing.com

    Ligand Pharmaceuticals (LGND) has reached a new 52-week high of $103.295, reflecting the company's strong financial performance and growth potential. The company has made several strategic moves, including acquiring APEIRON Biologics and expanding its credit facility, which have contributed to its positive market performance.

    Investing.com
    Featured Companies: AGEN
  • Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

    Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.

    Zacks Investment Research
    Featured Companies: ALXO BMY NERV
  • 3 Magnificent Growth Stocks to Buy Hand Over Fist

    Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.

    The Motley Fool
    Featured Companies: AGEN CGC

Related Companies

Page data last updated 09/06/2025 12:00:21 UTC